Dallas 2015 590: CPAP and IPPV In spontaneously breathing preterm infants with respiratory distress requiring respiratory support in the delivery room,

Slides:



Advertisements
Similar presentations
Dallas 2015 TFQO: Allan de Caen COI#38 EVREV 1: Melissa Parker COI#259 EVREV 1: Takanari Ikeyama COI#235 Taskforce: Pediatrics Peds 820 : The use of fluids.
Advertisements

Dallas 2015 TFQO: Myra Wyckoff #COI EVREV 1: Myra Wyckoff #COI EVREV 2: Lindsay Mildenhall #107 Taskforce: NRP NRP: 605 Two thumb verses two finger.
Dallas 2015 TFQO: Marya Strand, MD, MS; COI#222 EVREV 1: Marya Strand, MD, MS; COI#222 EVREV 1: Takahiro Sugiura, MD; COI#224 Taskforce: NLS Umbilical.
Chicago 2014 TFQO: Kee-Chong Ng (#COI = 113) EVREV 1: Gene Ong (#COI = 118) EVREV 2: Jos Bruinenberg (#COI = 19) Taskforce: Pediatric Taskforce The Long.
Dallas 2015 TFQO: S. Velaphi COI #242 EVREVs: N. Singhal COI#213 H. Ersdal COI#76 Taskforce: Neonatal Maintaining Infant Temperature During Delivery Room.
Dallas 2015 TFQO: EVREVs: de Almeida, Maria Fernanda COI# Trevisanuto, Daniele COI# Taskforce: Neonatal Warming Adjunts #599 Among preterm neonates who.
UOG Journal Club: September 2012 Perinatal outcome in women treated with progesterone for the prevention of preterm birth: a meta-analysis Sotiriadis A,
Chicago 2014 Peter Morley, Eddy Lang E3, GRADE expert Incorporating lower levels of evidence.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Oxygen Saturation Target Range for Extremely Preterm Infants Manja V, Lakshminrusimha.
Dallas 2015 TFQO: David Stanton COI 328 EVREVs: Volker Wenzel COI 253& Emmanuelle Bourdon COI 333 Taskforce: BLS Passive ventilation techniques.
Dallas 2015 TFQO: Karen Woolfrey COI #261 EVREV 1: Karen Woolfrey COI 261 EVREV 2: Daniel Pichel COI # 513 Taskforce: ACS ACS 335: Pre-hospital ADP- Receptor.
Dallas 2015 TFQO: Jerry Nolan #310 EVREV 1: Jerry Nolan COI #301 EVREV 2: Charles Deakin COI #221 Taskforce: ALS ALS 714 : Advanced airway placement (SGA.
Peds-818: Pediatric Early Warning Scores
Dallas 2015 TFQO: Karen Woolfrey COI #261 EVREV 1: Karen Woolfrey COI #261 EVREV 2: Daniel Pichel COI #513 Taskforce: ACS ACS 873: Pre-hospital STEMI Activation.
Dallas 2015 TFQO: Jeffry Pearlman COI# 187 EVREV 1: Enrique Udaeta COI# 239 EVREV 1: Edgardo Ezslyd COI# 277 Taskforce: NRP Laryngeal Mask Airway (NRP.
Felix I. Zemel, MPH DrPH Student Tufts University School of Medicine.
Dallas 2015 TFQO: EVREVs: Aaron Donoghue / Jonathan Duff Taskforce: EIT Teaching Compression-Only CPR.
Dallas 2015 TFQO: Masanori Tamura #147 EVREV 1: Masanori Tamura #147 EVREV 2: Susan Niermeyer #252 Delayed Cord Clamping in Preterm Infants Including those.
NRP: 862: Use of Feedback CPR Devices for Neonatal Cardiac Arrest NRP: 863: Use of Feedback CPR Devices to detect ROSC for Neonatal Cardiac Arrest TFQO:
Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants Intravenous immunoglobulin for suspected or subsequently.
Chicago 2014 TFQO: Peter Meaney #COI 149 EVREV 1: Richard Aickin #COI 153 EVREV 1: Peter Meaney #COI 149 Taskforce: Pediatrics Resuscitation fluids (Peds)
Dallas 2015 TFQO: Marilyn Escobedo COI#78 EVREV 1: Marilyn Escobedo COI#78 EVREV 2: Henry Lee COI#135 Taskforce: NRP Babies born to mothers who are hypothermic.
Dallas 2015 TFQO: Robert Greif EVREVs: Jan Breckwoldt, Henrik Fischer Taskforce: Education Implementation and Training (EIT) AED training methods.
Dallas 2015 TFQO: Enrique Udaeta COI# 239 EVREV 1: Enrique Udaeta COI# 239 EVREV 1: Edgardo Ezslyd COI# 277 Taskforce: NRP Laryngeal Mask Airway (NRP 618)
Dallas 2015 TFQO: EVREVs: Guinsburg, Ruth COI# McGowan, Jane COI# Taskforce: Neonatal Apgar Zero #896 In infants ≥36 weeks GA with an Apgar score.
Dallas 2015 TFQO: Name EVREV 1: Jonathan Wyllie COI #282 EVREV 1: Jeff Perlman COI #262 Taskforce: Newborn Temperature Maintenance in the Delivery room.
Chicago 2014 TFQO: Nikolaos Nikolaou COI#253 EVREV 1: Nikolaos Nikolaou COI#253 EVREV 2: Farzin BeyguiCOI#202 Taskforce: ACS STEMI transfer PCI vs. FL.
Chicago 2014 TFQO: Darren Walters COI #317 EVREV 1: Darren Walters COI #317 EVREV 2: Chris Ghaemmaghami COI #60 Taskforce: Acute Coronary Syndrome In STEMI.
Dallas 2015 TFQO: Anne-Marie Guerguerian # 97 EVREV1: Anne-Marie Guerguerian # 97 EVEREV2: Ericka Fink # 83 Taskforce: PEDS Peds 407 : ECMO for pediatric.
Clinical Writing for Interventional Cardiologists.
Dallas 2015 TFQO: Darren Walters EVREVs: EVREV 1: Darren Walters COI #422 EVREV 2: Chris Ghaemmaghami COI #89 Taskforce: Acute Coronary Syndrome Fibrinolytic.
First Aid 801: Stroke Recognition
Dallas 2015 TFQO: Name and #COI EVREV 1: Name and #COI Taskforce: Name Insert Short PICO title (including unique PICO ID#) Total of 4 (maximum) using standard.
Dallas 2015 TFQO: David Boyle COI #26 EVREV 1: David Boyle #COI#26 EVREV 1: Jane McGowan #370 Taskforce: Neonatal Ventilation Strategies in the DR (NRP.
Dallas 2015 TFQO: Name and #COI EVREV 1: Name and #COI Taskforce: Name Insert Short PICO title (including unique PICO ID#) Total of 6 (maximum) using standard.
WHO GUIDANCE FOR THE DEVELOPMENT OF EVIDENCE-BASED VACCINE RELATED RECOMMENDATIONS August 2011.
Dallas 2015 TFQO: Michael Sayre COI #400 EVREV 1: Mohamud Daya COI #327 EVREV 2: Jan-Thorsten Gräsner COI #230 Taskforce: BLS BLS 363: CPR Prior to Defibrillation.
Chicago 2014 TFQO: Charles Deakin #329 EVREV 1: Asger Granfeldt COI #63 EVREV 2: Bo Lofgren COI #363 Taskforce: ALS ALS 571 : Ventilation strategy post-ROSC.
Dallas 2015 TFQO: Allan de Caen COI #38 EVREV 1: Tia Raymond COI #153; EVREV 2: Jonathan Egan COI #44 Taskforce: Peds The role of invasive vascular monitoring.
UT Southwestern Medical Center at Dallas
Dallas 2015 TFQO: Kee-Chong Ng (#COI = 170) EVREV 1: Gene Ong (#COI = 118) EVREV 2: Jos Bruinenberg (#COI = 19) Taskforce: Pediatric Taskforce The Long.
Dallas 2015 TFQO: Vinay Nadkarni #375 EVREV 1: Vinay Nadkarni #375 EVREV 1: Dave Kloeck #126 Taskforce: Paeds Paed 424: Vasopressors in Paediatric cardiac.
Chicago 2014 Pediatric RRT/MET Teams #397 TFQO: Dianne Atkins COI #7 EVREV 1: Dianne Atkins EVREV 2: Kee Chong Ng COI #113 Taskforce: Peds.
TFQO: Jasmeet Soar #COI 272 EVREV 1: Jasmeet Soar #COI 272 EVREV 2: Michael Donnino #COI 222 Taskforce: ALS ALS 448 OXYGEN DOSE AFTER ROSC IN ADULTS 3.
Dallas 2015 TFQO: Maaret Castrén #320 EVREV 1: Christian Vaillancourt #416 EVREV 2: Michael Sayre #400 Taskforce: BLS BLS 359: Dispatcher Instructions.
Dallas 2015 TFQO: Jan Jensen COI #115 EVREVs: Jan Jensen COI #115 Richard N. Bradley COI #151 Taskforce: First Aid 769: Hemostatic Dressings.
Dallas 2015 TFQO: Monica Kleinman COI #353 EVREV 1: Janice Tijssen COI#232 EVREV 2: Javier Urbano COI#240 Taskforce: Peds Peds 815: Pediatric goal-directed.
Dallas 2015 TFQO: Judith Finn EVREVs: Judith Finn #227 / Dion Stub #COI Taskforce: EIT Cardiac Arrest Centres.
Dallas 2015 TFQO: Michael W. Donnino COI# EVREVs: Katherine M. Berg COI# Lars W. Andersen COI# Taskforce: ALS Ultrasound During CPR.
PVL_COUNTRY_DATE00/1 Département santé et recherche génésiquesDepartment of reproductive health and research Day 3 - Session 2 DAY (3) Session 2 Presentation:
Dallas 2015 TFQO: Jan Jensen COI #115 EVREV: Michael Reilly COI #193 Taskforce: First Aid First Aid 768: Use of Tourniquet.
Dallas 2015 TFQO: Koen Monsieurs 372 EVREV 1: Koen Monsieurs 372 EVREV 2: Ahamed Idris 349 Taskforce: BLS BLS366 Chest Compression Depth (adults)
Dallas 2015 TFQO: Jerry Nolan #310 EVREV 1: Jerry Nolan COI #301 EVREV 2: Jan-Thorsten Graesner COI #150 Taskforce: ALS ALS 783 : Advanced versus basic.
Dallas 2015 TFQO: Robert Greif EVREVs: Dana Edelson, COI #334 Robert Greif, COI #344 Taskforce: EIT EIT 645: Debriefing of resuscitation performance.
Dallas 2015 TFQO: Hiroshi Nonogi #254 EVREVs: Hiroshi Nonogi #254 Tony Scott #138 Taskforce: ACS Fibrinolytic and immediate PCI for STEMI 882.
Dallas 2015 TFQO: S. Velaphi EVREV 1: N. Singhal COI #213 EVREV 2: S. Velaphi COI #242 EVREV 3: H. Ersdal – COI # 76 Taskforce: NLS Prognosis: In newborn.
Dallas 2015 TFQO: Karen Woolfrey #COI 261 EVREV 1: Karen Woolfrey # COI 261 EVREV 2: Daniel Pichel #COI 513 Taskforce: ACS ACS 872: Pre-hospital Diversion.
Dallas 2015 TFQO: Name EVREVs: Names and #COI Taskforce: Name Insert Short PICO title Total of 12 (no studies) to 20 slides (maximum) using standard format.
Dallas 2015 TFQO: Jonathan Witt (COI #418) EVREVs: Steve Lin (COI #137), Thomas Pellis (COI #186) and Katie Dainty (COI #) Taskforce: ALS ALS 428 : Antiarrhythmic.
Chicago 2014 TFQO: Clifton Callaway # EVREV 1: Janice Zimmerman # EVREV 2: Jonathan Sullivan COI # Taskforce: ALS ALS 790 : Induced Hypothermia.
GRADE Grading of Recommendations Assessment, Development and Evaluation British Association of Dermatologists April 2014.
Dallas 2015 TFQO: Jasmeet Soar #COI 409 EVREV 1: Jasmeet Soar #COI 409 EVREV 2: Anthony Lagina #COI 357 Taskforce: ALS ALS 889 OXYGEN DOSE DURING CPR IN.
Dallas 2015 TFQO: Michael Donnino #222 EVREV 1: Joshua Reynolds COI #265 EVREV 2: Katherine Berg COI #10 Taskforce: ALS ALS 790 : Induced Hypothermia.
EVERETT F. MAGANN1 , KJELL HARAM2 , SONGTHIP OUNPRASEUTH1 , JAN H
UOG Journal Club: March 2017
25 – 26 March 2013 University of Oxford Intubation or CPAP ?
Feeding in Very Low Birth Weight neonates on Vapotherm versus CPAP
Why this talk? you will be seeing a lot of GRADE
Correlation of developmental outcome with severity of bronchopulmonary dysplasia in extremely low gestational age neonates Karen Belen, Chengqiu Lu, Narges.
UOG Journal Club: March 2017
Presentation transcript:

Dallas : CPAP and IPPV In spontaneously breathing preterm infants with respiratory distress requiring respiratory support in the delivery room, does the use of CPAP compared with intubation and IPPV improve outcome ? TFQO: B Stenson #274 EVREV 1: Tetsuya Isayama #113 EVREV 2: Ben Stenson #274 Taskforce: NRP

Dallas 2015 COI Disclosure B Stenson COI#274 Commercial/industry Nil relevant to this review Potential intellectual conflicts nil Tetsuya Isayama COI#113 Commercial/industry nil Potential intellectual conflicts nil

Dallas CoSTR “Spontaneously breathing preterm infants who have respiratory distress may be supported with CPAP or intubation and mechanical ventilation. The most appropriate choice may be guided by local expertise and preferences.”

Dallas 2015 C2015 PICO Population:Spontaneously breathing preterm infants with respiratory distress in the delivery room Intervention:CPAP Comparison:Intubation and IPPV Outcomes: Death or BPD -8, Death -9, BPD-7 Air leak -5, severe IVH-7, NEC -7, severe ROP - 7

Dallas 2015 Inclusion/Exclusion & Articles Found Inclusions/Exclusions Inclusion - Randomized controlled trials with the intervention allocated in the first 15 minutes after birth Exclusion – Randomized trials with later treatment allocation Lower levels of evidence Number of Articles initially identified, and number finally Included in Evidence Profile tables Found in Medline 469, Embase 679, Cochrane RCTs identified, RCTs - 3 included Other 3 RCTs were excluded because they were published only as abstracts. non-RCTs n/a

Dallas Proposed Treatment Recommendations For spontaneously breathing preterm infants with respiratory distress requiring respiratory support in the delivery room we suggest initial use of CPAP rather than intubation and IPPV (weak recommendation, moderate quality of evidence).

Dallas 2015 Risk of Bias in studies RCT bias assessment Allocation: Generation Allocation: Concealment Blinding: Participants Blinding: Assessors Outcome: Complete Outcome: Selective Other Bias Study Year Design Total Patients Population Industry Funding Morley 2008RCT wkGA with RD NoneLow HighLow Finer 2010RCT wkGANoneLow HighLow Unclear Dunn 2011RCT wkGANoneLow HighLow Unclear No blinding was done in all 3 trials but all outcomes assessed were objective. Two trials (Finer 2010 and Dunn 2011) included all infants at birth. Finer 2010 used different extubation criteria between the 2 groups.

Dallas 2015 Key data from key studies Death or BPD Death BPD

Dallas 2015 Key data from key studies Severe IVH NEC Air leak

Dallas 2015 Evidence profile table Quality assessmentEvent ratesEffect Quality Importan ce Study# & Design Risk of bias Inconsis tency Indirect ness Impreci sion OtherNCPAP Intubate & IPPV Relative (95% CI) Absolute (95% CI) Death or bronchopulmonary dysplasia (BPD) 3 RCT not serious 1 not serious serious 2 none 493/1193 (41.3%) 531/1165 (45.6%) RR 0.91 (0.83 to 1) 41 fewer per 1000 (0 fewer−77 fewer) ◯ MODERA TE CRITICAL (8) Bronchopulmonary dysplasia (BPD) 3 RCT not serious 1 not serious serious 2 none 370/1070 (34.6%) 384/1018 (37.7%) RR 0.92 (0.82 to 1.03) 30 fewer per 1000 (11 more−68 fewer) ◯ MODERA TE CRITICAL (7) Death 3 RCT not serious 1 not serious serious 2 none 123/1193 (10.3%) 147/1165 (12.6%) RR 0.82 (0.66 to 1.03) 23 fewer per 1000 (4 more−43 fewer) ◯ MODERA TE CRITICAL (9) Three RCTs (Morley 2008, Finer 2010, and Dunn 2011) were included. 1.Interventions were not blinded but outcomes were objective. 2.The 95%CI included the null or minimal (negligible) harm (RR )

Dallas 2015 Evidence profile table Quality assessmentEvent ratesEffect Quality Importan ce Study# & Design Risk of bias Inconsi stency Indirect ness Impreci sion OtherNCPAP Intubate & IPPV Relative (95% CI) Absolute (95% CI) Severe intraventricular hemorrhage (Severe IVH) 3 RCT not serious 1 serious 2 not serious very serious 4 none 125/1167 (10.7%) 112/1134 (9.9%) RR 1.09 (0.86 to 1.39) 9 more per 1000 (14 fewer−39 more) ◯◯◯ VERY LOW CRITICAL (7) Air leak 3 RCT not serious 1 serious 3 not serious serious 5 none 85/1192 (7.1%) 67/1165 (5.8%) RR 1.24 (0.91 to 1.69) 14 more per 1000 (5 fewer−40 more) ◯◯◯ LOW IMPORTANT (5) Severe retinopathy of prematurity (Severe ROP) 2 RCT not serious 1 not serious very serious 4 none 80/703 (11.4%) 72/656 (11.0%) RR 1.03 (0.77 to 1.39) 3 more per 1000 (25 fewer−43 more) ◯◯◯ LOW CRITICAL (7) Necrotizing enterocolitis (NEC) 3 RCT not serious 1 not serious serious 5 none 113/1183 (9.6%) 92/1148 (8.0%) RR 1.19 (0.92 to 1.55) 15 more per 1000 (6 fewer−44 more) ◯◯◯ MODERA TE CRITICAL (7) Three RCTs (Morley 2008, Finer 2010, and Dunn 2011) were included, except for severe ROP in which two RCTs (Finer 2010 and Dunn 2011) were included. 1.Interventions were not blinded but outcomes were objective. 2.I-square = 52% 3.I-squared = 75%. Air leak was increased in the CPAP group in one trial (Morley 2008). In this trial the initial CPAP was at 8cmH2O and the criteria for intubation was an oxygen requirement of 60%. 4.The 95% CI were wide and included both clinically important benefit (RR 1.1) 5.The 95%CI included the null or minimal (negligible) harm (RR )

Dallas 2015 Proposed Consensus on Science statements For the critical composite outcome of “death or bronchopulmonary dysplasia” we have identified moderate quality evidence (downgraded for imprecision) from 3 RCTs (Morley , Finer , Dunn 2011 e1069) enrolling 2358 preterm infants born at < 30 weeks gestation in the first 15 minutes after birth showing modest potential benefit to starting treatment with CPAP (R.R. 0.91, 95% CI 0.83 – 1.00). For the critical outcome of “death” we have identified moderate quality evidence (downgraded for imprecision) from the same 3 RCTs (Morley , Finer , Dunn 2011 e1069) showing modest potential benefit to starting treatment with CPAP (R.R. 0.82, 95% CI 0.66 – 1.03). For the critical outcome of “bronchopulmonary dysplasia” we have identified moderate quality evidence (downgraded for imprecision) from the same 3 RCTs (Morley , Finer , Dunn 2011 e1069) showing modest potential benefit to starting treatment with CPAP (R.R. 0.92, 95% CI 0.82 – 1.03).

Dallas 2015 Proposed Consensus on Science statements For the critical outcome of “air leak” we have identified low quality evidence (downgraded for inconsistency and imprecision) from the same 3 RCTs (Morley , Finer , Dunn 2011 e1069) showing no benefit to starting treatment with CPAP (R.R 1.24, 95% CI 0.91 – 1.69). For the critical outcome of “severe intraventricular haemorrhage” we have identified very low quality evidence (downgraded for inconsistency and very serious imprecision) from the same 3 RCTs (Morley , Finer , Dunn 2011 e1069) showing no benefit to starting treatment with CPAP (R.R 1.09, 95% CI 0.86 – 1.39).

Dallas 2015 Proposed Consensus on Science statements For the important outcome of “necrotizing enterocolitis” we have identified moderate quality evidence (downgraded for imprecision) from the same 3 RCTs (Morley , Finer , Dunn 2011 e1069) showing no benefit to starting treatment with CPAP (R.R % CI 0.92 – 1.55). For the important outcome of “severe retinopathy of prematurity” we have identified low quality evidence (downgraded for very serious imprecision) from 2 RCTs (Finer , Dunn 2011 e1069) enrolling 1359 infants showing no benefit to starting treatment with CPAP (R.R % CI ).

Dallas 2015 Draft Treatment Recommendations For spontaneously breathing preterm infants with respiratory distress requiring respiratory support in the delivery room we suggest initial use of CPAP rather than intubation and IPPV (weak recommendation, moderate quality of evidence). Values and preference statement: In making this suggestion we recognize that the absolute reduction in risk of adverse outcome associated with starting with CPAP is small and that infants recruited to the trials had a high rate of treatment with antenatal steroids but we favor the less invasive approach. The balance of risks and benefits of this approach in infants who have not received antenatal steroids is unknown.

Dallas 2015 Knowledge Gaps A further trial of CPAP versus intubation and IPPV in high risk preterm infants at lower gestations is required to determine the risks and benefits more clearly. It is not clear whether there is a significant effect on mortality. The confidence intervals for the other morbidities of prematurity leave open the possibility that any benefit in relation to bronchopulmonary dysplasia might still be balanced by a small increase in risk of severe intraventricular haemorrhage or necrotizing enterocolitis. The utility of using an INSURE approach to facilitate early stabilization on CPAP soon after birth has been compared with CPAP alone in at least 2 trials and this should be the subject of a future worksheet.

Dallas 2015 Next Steps This slide will be completed during Task Force Discussion (not EvRev) and should include: Consideration of interim statement Person responsible Due date Essential slide (one slide only). Estimated time <30 sec